Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Top Cited Papers
- 1 May 2008
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 371 (9625), 1675-1684
- https://doi.org/10.1016/s0140-6736(08)60726-6
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisCurrent Medical Research and Opinion, 2007
- Pathogenesis and therapy of psoriasisNature, 2007
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesisThe Journal of Experimental Medicine, 2006
- Adherence to treatment in patients with psoriasisJournal of the European Academy of Dermatology and Venereology, 2006
- Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodiesJournal of Pharmaceutical and Biomedical Analysis, 2005
- PsoriasisNew England Journal of Medicine, 2005
- A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque PsoriasisJournal of Investigative Dermatology, 2004
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004